Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.

Autor:	Bachelard, Antoine, Hingrat, Quentin Le, Ferré, Valentine-Marie, Lê, Minh, Peytavin, Gilles, Damond, Florence, Charpentier, Charlotte, Goudot, Guillemette Fremont, Bouille, Jeanne Goupil de, Lariven, Sylvie, Delobel, Pierre, Yazdanpanah, Yazdan, Descamps, Diane, Matheron, Sophie, Ghosn, Jade, group, for the ANRS CO05 VIH-2 cohort study
Předmět:	THERAPEUTIC use of monoclonal antibodies KIDNEY function tests PATIENT compliance VIRAL load RESEARCH funding SALVAGE therapy SCIENTIFIC observation DRUG resistance in microorganisms CD4 lymphocyte count MULTIDRUG resistance HIV infections TREATMENT effectiveness BLOOD cell count DESCRIPTIVE statistics ANTIVIRAL agents COMBINED modality therapy RESEARCH BLOOD plasma ANTI-HIV agents DRUGS GENETIC mutation TIME LIVER function tests DRUG tolerance
Zdroj:	Clinical Infectious Diseases; 4/15/2024, Vol. 78 Issue 4, p1005-1010, 6p
Abstrakt:	We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu